Haifa, Israel; Boston, MA – March 7, 2022 – MeMed today announced that it has been named by Fierce Medtech as one of its ‘Fierce 15’ medical technology companies of 2021, designating it as one of the ...

—MeMed BV Flex™ simultaneously measures multiple host proteins, paired with machine learning, to deliver highly accurate results in 15 minutes from just a few drops of blood— —Designed for use in ...

Israel’s MeMed Diagnostics, a Haifa-based medical tech firm that develops diagnostic solutions to monitor the body’s immune state, raised $93 million in a private financing round to help commercialize ...

– Milestone Achieved Through Growing Clinical Evidence Demonstrating Real-World Impact on Infection Management – – MeMed and Physicians Premier Celebrated Milestone Event in Corpus Christi, Texas – ...

MeMed has developed MeMed BV Flex, a rapid infection differentiation test that distinguishes between bacterial and viral infections. This test is set to widen the accessibility of MeMed BV to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. MeMed Ltd. announced that it has received a government ...

While most infectious disease tests search a sample for the presence of a particular pathogen, MeMed’s diagnostic collects evidence from the immune system itself and helps identify the culprit by ...

MeMed today announced publication of the results of a large multicenter prospective clinical study that validates the ability of its ImmunoXpert in-vitro diagnostic blood test to determine whether a ...

HAIFA, Israel, Jan. 12, 2026 /PRNewswire/ -- MeMed, the leader in host-response diagnostics, announced it has been awarded a competitive national grant through the IIA to establish an acute-care ...

MeMed partners with Italy’s DiaSorin to commercialize bacteria vs virus test Test to be integrated in over 5,000 DiaSorin analyzers, allowing physicians to differentiate between bacterial and viral ...

Israeli diagnostics company MeMed was just awarded $9.2 million from the U.S. Defense Threat Reduction Agency (DTRA) to develop a faster instrument to differentiate between bacterial and viral ...